Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its clinical development of LUCID-MS, a proprietary therapy candidate for multiple sclerosis. The therapy targets demyelination and aims to protect or restore myelin integrity, addressing a key underlying mechanism of the disease. Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and general tolerability, supporting the progression into patient-focused studies.
In April 2026, the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. Quantum BioPharma believes the therapy may offer a differentiated, potentially first-in-class approach because it directly addresses myelin loss and neurodegeneration rather than relying solely on immune modulation. The program is also bolstered by a planned partnership with Allucent and engagement with neurological specialists.
The implications of this announcement are significant for the multiple sclerosis treatment landscape. Current therapies predominantly focus on immune modulation to reduce relapses, but they do not effectively halt or reverse neurodegeneration. LUCID-MS, if successful, could represent a paradigm shift by directly targeting myelin repair and neuroprotection. This could potentially slow disease progression and improve quality of life for millions of MS patients worldwide.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company also retains ownership in Unbuzzd Wellness Inc., which markets unbuzzd, an OTC product. Quantum BioPharma retains 19.84% of UWI and receives royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of rights to develop similar products for pharmaceutical and medical uses.
For more information, visit the company's newsroom at https://ibn.fm/QNTM.
